London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East and have access to Premium Chat. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Never a good sign when the Doctors wearing a glove commonly seen on the arm of a farming veterinarian
Had something similar happen to me,Doctor told me to bend over,He then told me I’m might feel a little prick .
After my prostate exam, the doctor left. The nurse came in later, with a worried look on her face, and said the three words I was dreading to hear.. .
Who was that?
You're not Ben Doon and Phil McCavity respectively are you¿¿
Where shall i put my trousers?. On the chair next to mine.....
Lmao thoth. Thumbs up to that joke ??
I always dread the sound of rubber gloves in these situations!!
Thoth you only have to worry when he has two hands on your shoulders
Thoth - Could be worse, he could insist on spooning afterwards.
Reminded me of mylast prostate exam. Doctor mutttered "dont worry its perfectly normal to get an erection in this situation." I responded i was fine. He said "i was talking to myself".
SOG thanks for posting those links. Until 1801 unleashed on humans and data released we just have to hope that we’re mostly clean.
Sog. That's a great joke. Loved it
Reminds me of a very old joke Carter 19.
An elderly couple went to the doctors. Chronic constipation was diagnosed. The doctor prescribed them some suppositories.
The elderly couple returned home and duly read the instructions. One to be inserted up the anus once per day. The old boy says. ' ere Ethel what the f..k is an anus? I don't know Ethel replies but we have a dictionary and we can look it up. Ethel meanders over to the sideboard picks up the dictionary and opens it. I have found it she says. What is it then Bert asks?
It's a back passage Ethel replies.
We have a back passage that leads away from the back door he says. We are very fortunate to have found it.
Every morning they open the back door and throw out 2 of these suppositories.
2 weeks later they return to the doctors.
Good morning Bert and Ethel the doctor says, how are you getting on with your medications?
Not good at all says Bert we both took them as directed but condition has got worse. I am not happy at all with them. For what good they have done, we might just as well stuck them up our ar5e.
Good post Citizen79. Apologies but have only just scrolled down to your post.
Important to look at all sides of the battle, Where and why others fail , why some succeed and others do not. Attention to detail. All have plusses and minuses.
I am fine thankyou and trust likewise you are the same sir.
Regards and keep those post coming, knowledge is power.
i will add that phase 1/2 data may not bring to a head the development of heart problems.
Deucracitinib is pure Tyk 2 and failed in IBD ie UC. maybe looking at trialing woth kigher doses. Higher dose of course leads to higher risk'
As far as I can tell 1L-10 inhibition is of paramount importance in treatment of IBD. IL-10 consists of 4 sub units 2 of which are Jak 1 and 2 of which Tyk2. Without this I reckon they are pretty will phu..ed in this indication.
Pfizer have gone the Tyk2 Jak1 route. They have not made public any severe side affects at the moment. They may be minor or major ones.
An inhibitor is a tool, nothing else. if we do not use this tool correctly it will fail. In this instance dosing regime with how much and to what frequency will give optimum results cannot be over estimated. Drug companies are outsourcing to specialist companies in this field. You cam include if you wish the acquisition of a company. Why? They do not have the knowhow themselves. ) Lucrative markets cost of initial investment and nippy bum time come to mind)
Discovery of Tyrosine Kinase 2 (TYK2) Inhibitor (PF-06826647) for the Treatment of Autoimmune Diseases. This was discontinued at end of 2021. I would summise as pure Tyk2 only
Enough from me.
Regards to all and enjoy what left of weekend.
Well, the vaccines are killing people as well, I know over 20 that have been to hospital, heart attacks or chest pains, blood clots and other problems, everyone double or triple vaccinated. Herd immunity was achieved several mths ago and those test kits are useless, might as well stick them up your anus, that might be positive though. Let’s not forget, these are 2 year experimental jabs.
Good evening ndr50.
Cannot locate original links I had. This one will indicate that kinase inhibitors carry a risk of heart problems. Not all bad I might add. it has been know about for some time. Not really been a topic of that has raised its ugly head. Mainly but not wholly caused by off target inhibition. Very early link to ICR for CHK 1 inhibitor indicates the pedigree we have in our drug design and formulations also added here.
It does point to a need to have extreme purity in compound formulation.
Tim and Co I am certain will be aware of this and taken into consideration. Am making a guess as to why so much precision, attention to detail put into its inhibitors.. We must also bare in mind that these effects would have happened to early designs and compound creations, whereby a pharma will focus on what a compound can do without the same amount of attention to the side effects.
I will reiterate that I do not see this as a major concern. We have no idea how much and how far Tim and co have addressed this problem as any information regarding this will be commercially very sensitive. Clearly they are very confident.
PS Sometimes it may appear I am ramping like hell. But if I think there are areas not looking so positive I will post so as to raise debate. It is not fear of the known which troubles us it is fear of the unknown.
Interesting post SOG. I was under the impression that the phase 1/2 data for Pfizer’s Tyk2/Jak1 proceeded without any significant adverse effects. Is the myocardial issue something that has been found recently? As for 1801/1802 being best in class that remains an aspiration rather than a certainty atm, time will tell ultimately after phase 3 complete for whatever indication. That’s sometime away and I imagine most PI s will have bailed before then.
(replying to the correct thread)
Maidit- to quote:
"over the years is becoming a joke.. H2 should have been June half, year,
and not July or August into Q3 , if it's going to be change to q3 tell us before deadline run out,
not after, as the Market is unforgiving when you mess with the expectation,"
You are deliberately misleading the board here. The AGM statement clearly stated" during mis-2022"
" The data from these studies will be crucial to the progression of this CTA, which we remain on track to submit during mid-2022."
Please provide a clear example of where SAR have missed a deadline.
Siennaj, pharma is a very slow moving business. We’re now closer than ever with achieving our goals.
Excellent posts SOG, I trust you are well.
You are right to highlight Myocardial issues.
I was reading this earlier:
Should have read Parker
I may be slaughtered for this but considering most here feel Sar have the cure within their various products for every disease known to the human race who at Sar is selling or negotiating or doing anything to push this because all I can see is long term and incredibly patient shareholders blowing the trumpet and all PRket does is tweet on twitter to keep interest going but there are still no sales and no contracts and no money!!!
I think we would definitely have the edge in IBD. Jak1 Jak2 okish, tyk 2 Jak2 bloody pointless. Jak1 Tyk 2 very good Indications. No adverse side effects from infections. We will have excellent LADMET especially in capsule formulations. Only downside l can see and the most likely is a dose related affect being mycocardia. It apparently has been identified in small kinase inhibitors but kept rather quiet. However, thus may be because other side effects established themselves long before continued doses reached an alarming degree of mycocardia.
Toxicity will be reached at some point. I feel.we are in an extremely strong position
Much attention to detail has gone into the development. As someone stated earlier we have outsourced when required to the best people in the world. Funnily enough GSK aint one of them .
The real biggy will be stage 1 clinical trial results. Our compounds are at least good if not the best. They are also extremely well protected by patents. Compatible with nigh every other type of compound going..
Sareum should have a pretty good idea what Indications to go for. After all it is they who designed the inhibitor to treat the targeted areas in the first place.
Immunotherapy therapy is vast and more than 1 type of inhibitor will be required for many years to come. The more you look into.it the more complex it becomes. There is a bloody big market out there for treatments. I am not for one moment suggesting we will capture the entire market, more along the lines of a very comfortable share of. Enough to make many financially very comfortable.
I look in here most days read some of the interesting posts and that is about it. It is good to leave the share chat for a while. I think it enables us to evaluate things looking from outside the bowl.
SOG - I certainly don't envy the task our BoD have in choosing the initial target for a compound. I'm picturing a sliding scale where at one end we try to muscle-in on an established high-value market and at the other end you have the chance of being the only drug of choice albeit in a smaller market.
No doubt this is where the various consultants we employ will earn their keep but at least it would appear 1801/2 could be highly effective in multiple indications.